The benefits of using a nimble platform from phase to phase
By streamlining data entry and reducing complex paperwork, digital platforms can reduce costs and timelines for clinical trials. While SaaS…
sponsored
-
-
Pancreatic cancer: The clinical trial landscape and progress for 2024
Pancreatic cancer is an extremely aggressive disease that forms in the tissues of the pancreas, which plays a crucial role…
-
Podcast: How drones are transforming the clinical supply chain in Africa
Africa has the highest disease burden of any continent in the world. With arguably the most diverse range of environments,…
-
Why the Importer of Record (IoR) is vital in the clinical supply chain
With imports fundamental to the clinical supply chain, a specialist Importer of Record (IoR) can make all the difference in…
-
The value of CNS-specific eCOA provider in clinical trials
The pharmaceutical industry is continuously evolving, driven by the imperative to develop more effective and personalized treatments. In this dynamic…
-
Oesophageal cancer: the global clinical trials landscape in 2024
Oesophageal cancer is the 11th most diagnosed cancer and the 7th leading cause of cancer mortality. The disease starts in…
-
Secondary packaging for sterile injectables: Overcoming today’s design challenges
The market for injectables is surging, with autoinjectors growing due to their convenience in allowing patients to self-administer medication instead…
-
Overcoming common challenges in fill/finish for monoclonal antibodies (mAbs)
Monoclonal antibodies (or mAbs) are a class of therapeutic proteins designed to target specific molecules or cells in the body.…
-
Safety first: Cognition as a primary safety endpoint provides a competitive advantage
In the evolving landscape of clinical research, the incorporation of cognition into the safety profiles of both CNS and non-CNS…
-
Addressing industry challenges through flexible, personalized eCOA solutions
Electronic clinical outcome assessment (eCOA) has become an essential tool for capturing patient data, but one critical challenge continues to…
